4. As of noon trading, Vertex Pharmaceuticals ( VRTX) is down $0.72 (-1.8%) to $39.07 on light volume Thus far, 510,962 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $38.95-$40.07 after having opened the day at $39.82 as compared to the previous trading day's close of $39.79. Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. Vertex Pharmaceuticals has a market cap of $8.6 billion and is part of the drugs industry. The company has a P/E ratio of 64.1, above the S&P 500 P/E ratio of 17.7. Shares are up 19.7% year to date as of the close of trading on Friday. Currently there are 13 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold. TheStreet Ratings rates Vertex Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. Get the full Vertex Pharmaceuticals Ratings Report now. EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass
Community Health Systems may close its $7.6 billion acquisition of Health Management Associates, but with the uncertainties of a new healthcare law and the merger partners' own legal problems, it needed good timing to put reasonable financing in place.